I have written often here on my blog about low-dose naltrexone (LDN), a medication that is used in tiny doses to help normalize the immune system in a wide range of medical conditions and diseases, including ME/CFS, fibromyalgia, and Lyme disease. My son and I have both taken LDN for 10 years now, and it has helped us a lot. I felt better - less fatigue, more energy, more alert, improved mental clarity - from the very first morning after I took my first bedtime dose. You can read all about LDN, what it is, how it works, and our experiences with it in this post.
There have been hundreds of research studies on the use of LDN over the past 20+ years (unfortunately, as you might expect from our lack of research funds, none yet on ME/CFS), including some very positive studies on using LDN for fibromyalgia. You can see a long list of LDN research studies, conducted from 1991 through 2013.
So, the reason for this new post is that the LDN Research Trust is hosting its annual LDN Conference in Portland, Oregon, on September 21-24. In addition to attending the conference (which probably few of us can manage), they are providing recorded presentations with pdf downloaded documents via a Livestream option so that anyone, anywhere can watch the presentations of interest to them (at any time - they don't have to be watched live). You can even get Continuing Education Credits from some of the Livestream options.
Some of the presentations included are on the topics of using LDN in:
- Thyroid disease
- For children
- Lyme disease and other tick infections (multiple presentations)
- Autism Spectrum Disorder (there has been extensive research on LDN for autism in kids)
- Inflammatory Bowel Disease
- Celiac Disease
- POTS (a type of Orthostatic Intolerance which is an integral part of ME/CFS)
- Bipolar Disorder
- Hashimoto's disease
- and more!